Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pozelimab and Cemdisiran Combination in PNH Patients Transitioning from Pozelimab Monotherapy
NCT04811716Phase 2Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Jul 2021
- Primary completion
- Oct 2022
- Modality
- Antisense DNA, Recombinant Proteins and Enzymes, Conjugated siRNA
- Countries
- 6
01
Overview
A Phase 2 trial of pozelimab, cemdisiran in paroxysmal nocturnal hemoglobinuria (PNH), sponsored by Regeneron Pharmaceuticals. Started Jul 2021; status: completed.
02
Drugs
pozelimabcemdisiran
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on NCT04811716.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04811716.